Class: Disease-modifying Antirheumatic Drugs
- Disease-modifying Antirheumatic Drugs
- DMARDs
CAS Number: 170277-31-3
Brands: Inflectra, Remicade
Medically reviewed by Drugs.com. Last updated on May 11, 2020.
Warning
- Serious Infections
-
Increased risk of serious infections that may require hospitalization or result in death, particularly in patients receiving other immunosuppressive agents concomitantly; tuberculosis (frequently disseminated or extrapulmonary), invasive fungal infections (may be disseminated), bacterial (e.g., legionellosis, listeriosis) and viral infections, and other opportunistic infections reported.1 72 155 159 167 (See Infectious Complications under Cautions.)
-
Carefully consider risks and benefits prior to initiating therapy with infliximab products in patients with chronic or recurring infections.1 159 167
-
Evaluate patients for latent tuberculosis infection prior to and periodically during therapy with infliximab products; if indicated, initiate appropriate antimycobacterial regimen prior to initiating infliximab products.1 72 118 159 167
-
Closely monitor patients for infection, including active tuberculosis in those with a negative tuberculin skin test, during and after treatment.1 167 Discontinue infliximab product if serious infection or sepsis occurs.1 34 35 44 118 167 Consider empiric antifungal therapy if serious systemic illness occurs in a patient at risk for invasive fungal infections.1 155 159 167 Serologic tests for histoplasmosis may be negative.1 167
- Malignancy
-
Lymphoma and other malignancies (some fatal) reported in children and adolescents receiving TNF blocking agents.1 154 160 167 (See Malignancies and Lymphoproliferative Disorders under Cautions.)
-
Aggressive, usually fatal hepatosplenic T-cell lymphoma reported mainly in adolescent and young adult males with Crohn's disease or ulcerative colitis receiving TNF blocking agents, including infliximab products.1 154 160 167 Most of the patients received a combination of immunosuppressive agents, including TNF blocking agents and thiopurine analogs (azathioprine or mercaptopurine).1 154 160 167
Introduction
In this monograph, unless otherwise stated, the term “infliximab products” refers to infliximab (the reference drug), infliximab-dyyb (the biosimilar), or both drugs.
Biologic response modifiers and disease-modifying antirheumatic drugs (DMARDs); chimeric human-murine monoclonal antibodies that block the biologic activity of tumor necrosis factor (TNF, TNF-α).1 7 20 24 167 173 174 175 176 177
Infliximab-dyyb is biosimilar to infliximab (Remicade).167 168 173 174 175 176 177 192 A biosimilar is a biological that is highly similar to an FDA-licensed reference biological with the exception of minor differences in clinically inactive components and for which there are no clinically meaningful differences in safety, purity, or potency.168 170 171 172 Biosimilars are approved through an abbreviated licensure pathway that establishes biosimilarity between proposed biological and reference biological but does not independently establish safety and effectiveness of the proposed biological.169 170 171 179 Infliximab-dyyb is considered a therapeutic alternative to infliximab; not interchangeable.168 170 172 180
Uses for Infliximab, Infliximab-dyyb
Crohn’s Disease (Infliximab or Infliximab-dyyb)
Used to reduce signs and symptoms of Crohn’s disease and to induce and maintain clinical remission in adults and pediatric patients with moderate to severe active disease who have had an inadequate response to conventional therapies (e.g., corticosteroids, mesalamine or sulfasalazine, azathioprine or mercaptopurine).1 5 6 38 51 72 89 136 142 167 (See Pediatric Use under Cautions.)
Used to reduce the number of draining enterocutaneous and rectovaginal fistulas and to maintain fistula closure in adults with fistulizing Crohn’s disease (designated an orphan drug by FDA for this use).1 64 94 140 141 142 143 167 Consider use when fistulas have not responded to appropriate anti-infective regimens (e.g., ciprofloxacin and/or metronidazole) and/or immunosuppressive therapy (e.g., azathioprine or mercaptopurine).47 65 66 70
Rheumatoid Arthritis in Adults (Infliximab or Infliximab-dyyb)
Used in conjunction with methotrexate to manage the signs and symptoms of rheumatoid arthritis, to improve physical function, and to inhibit progression of structural damage associated with the disease in adults with moderate to severe active rheumatoid arthritis.1 14 15 17 18 41 167
Ankylosing Spondylitis (Infliximab or Infliximab-dyyb)
Management of the signs and symptoms of active ankylosing spondylitis.1 72 108 109 117 137 138 167
Psoriatic Arthritis (Infliximab or Infliximab-dyyb)
Used to manage the signs and symptoms of active arthritis, inhibit progression of structural damage associated with the disease, and improve physical function in adults with psoriatic arthritis.1 72 105 106 107 108 131 167
Plaque Psoriasis (Infliximab or Infliximab-dyyb)
Management of chronic, severe (i.e., extensive and/or disabling) plaque psoriasis in adults who are candidates for systemic therapy and in whom other systemic therapies are medically less appropriate.1 167 Use only in patients who will be closely monitored and who will have regular follow-up visits with a clinician.1 167
Ulcerative Colitis (Infliximab or Infliximab-dyyb)
Used to manage the signs and symptoms, to induce and maintain clinical remission and mucosal healing, and to eliminate corticosteroid use in adults with moderate to severe active ulcerative colitis who have had an inadequate response to conventional therapies.1 47 72 112 113 114 147 167
Infliximab used to manage the signs and symptoms and to induce and maintain clinical remission in pediatric patients with moderate to severe active ulcerative colitis who have had an inadequate response to conventional therapies (designated an orphan drug by FDA for treatment of ulcerative colitis in pediatric patients191 ).1 Although safety and efficacy of infliximab-dyyb for such use also established, labeled indication for infliximab in pediatric patients with ulcerative colitis was still protected by exclusivity provisions of orphan drug designation when FDA approved infliximab-dyyb biosimilar.167 168 (See Pediatric Use under Cautions.)
Juvenile Arthritis (Infliximab)
Has been used in a limited number of pediatric patients with juvenile arthritis†; further study needed.1 72 103 104 153
Behcet’s Syndrome (Infliximab)
Has been used in a limited number of patients with Behcet’s syndrome†.93 102 115 116
Infliximab, Infliximab-dyyb Dosage and Administration
General
Premedication and Patient Monitoring
-
Consider administration of premedication prior to each dose to minimize risk of infusion-related reactions.1 47 72 167
-
Patients receiving initial infusion and patients without a history of acute infusion reactions: Oral diphenhydramine hydrochloride (25–50 mg) and acetaminophen (650 mg) can be given before the infusion.47 72
-
Patients with a history of acute infusion reactions: Oral or IV prednisone (40 mg) or hydrocortisone (100 mg), oral or IV diphenhydramine hydrochloride (25–50 mg), and acetaminophen (650 mg) can be given before the infusion.72 142
-
Monitor patients closely during and after each IV infusion.72 Measure vital signs (pulse and BP) immediately prior to infusion, during the infusion (every 30 minutes in patients without a history of acute infusion reactions and every 15 minutes in those with a history of reactions), and for 30 minutes after completion of the infusion.72
-
If DBP drops 15–20 mm Hg or symptoms of hypersensitivity (e.g., urticaria, shortness of breath) occur, stop the infusion immediately, evaluate manifestations, and initiate appropriate therapy.72
-
If the reaction is not severe and is mitigated with a regimen of oral diphenhydramine hydrochloride (25–50 mg), oral acetaminophen (650 mg), and oral or IV prednisone (40 mg), the infusion may be resumed with caution following the rate titration schedule using an initial rate of 10 mL/hour.72 (See Rate Titration Schedule Table under Dosage and Administration.)
-
The infusion should be discontinued and not completed if the reaction does not resolve with the regimen described above or is more severe and/or requires treatment with epinephrine.72
Concomitant Therapy for Crohn’s Disease
-
Corticosteroids, mesalamine, sulfasalazine, azathioprine, mercaptopurine, methotrexate, and anti-infective agents may be continued.1 167
-
When deciding whether to use infliximab products alone or in combination with other immunosuppressive agents (e.g., azathioprine, mercaptopurine), consider both the possibility of an increased risk of hepatosplenic T-cell lymphoma with combination therapy and the observed (in infliximab studies) increase in immunogenicity and hypersensitivity reactions associated with infliximab products given as monotherapy.1 167 (See Malignancies and Lymphoproliferative Disorders, Acute Sensitivity Reactions, and Delayed Sensitivity Reactions, under Cautions.)
Concomitant Therapy for Rheumatoid Arthritis
-
Intended for use concomitantly with methotrexate; only limited data available regarding the efficacy of infliximab products without concomitant methotrexate.1 17 18 20 21 23 167
Concomitant Therapy for Psoriatic Arthritis
-
Corticosteroids, NSAIAs, and methotrexate may be continued.1
Concomitant Therapy for Ulcerative Colitis
-
Corticosteroids, azathioprine, mercaptopurine, and 5-aminosalicylates may be continued.1 147
-
When deciding whether to use infliximab products alone or in combination with other immunosuppressive agents (e.g., azathioprine, mercaptopurine), consider both the possibility of an increased risk of hepatosplenic T-cell lymphoma with combination therapy and the observed (in infliximab studies) increase in immunogenicity and hypersensitivity reactions associated with infliximab products given as monotherapy.1 167 (See Malignancies and Lymphoproliferative Disorders, Acute Sensitivity Reactions, and Delayed Sensitivity Reactions, under Cautions.)
Reinitiation of Treatment
-
Carefully consider risks and benefits of readministration of infliximab or infliximab-dyyb after a period without treatment (especially readministration as a reinduction regimen at 0, 2, and 6 weeks); in patients with psoriasis, reinitiate treatment with a single dose followed by maintenance therapy.1 167 (See Acute Sensitivity Reactions and also Delayed Sensitivity Reactions, under Cautions.)
Administration
IV Administration (Infliximab or Infliximab-dyyb)
For solution and drug compatibility information, see Compatibility under Stability.
Administer by IV infusion.1 167
Administer with an in-line, sterile, nonpyrogenic, low-protein-binding filter with a pore diameter of ≤1.2 µm.1 167
Consult respective manufacturer’s labeling for additional information on reconstitution, dilution, and administration of infliximab or infliximab-dyyb.1 167
Reconstitution
Reconstitute vial containing 100 mg of infliximab or infliximab-dyyb powder with 10 mL of sterile water for injection to provide a solution containing 10 mg/mL.1 167 Reconstitute the number of vials needed to provide the indicated dosage of infliximab or infliximab-dyyb.1 167
Direct diluent toward the side of the vial with a sterile syringe and a 21-gauge or smaller needle; swirl vial gently to ensure dissolution; do not shake or agitate vigorously (to avoid foaming).1 167
Allow reconstituted solution to stand for 5 minutes before dilution.1 167
Dilution
Remove the volume of diluent equal to the total required volume of reconstituted infliximab or infliximab-dyyb solution from a 250-mL bag or bottle of 0.9% sodium chloride injection.1 167 Slowly add reconstituted infliximab or infliximab-dyyb to the bag to yield a total volume of 250 mL; mix gently.1 167 Concentration of the solution for infusion should be 0.4–4 mg/mL.1 167 Begin infliximab or infliximab-dyyb infusion within 3 hours of reconstitution and dilution.1 167
Rate of Administration
Infuse infliximab or infliximab-dyyb over a period of at least 2 hours.1 167
Manufacturer of infliximab states that IV infusions may be given at a rate of 2 mL/minute or, alternatively, a rate titration schedule may be used in an attempt to prevent or ameliorate acute infusion reactions.72 A rate titration schedule can be used in patients receiving an initial infliximab dose, those without a history of acute infusion reactions, and those with a history of such reactions.72
Rate |
Time |
---|---|
10 mL/hour |
first 15 minutes72 |
20 mL/hour |
next 15 minutes72 |
40 mL/hour |
next 15 minutes72 |
80 mL/hour |
next 15 minutes72 |
150 mL/hour |
next 30 minutes72 |
250 mL/hour |
next 30 minutes72 |
Dosage
Pediatric Patients
Crohn’s Disease (Infliximab or Infliximab-dyyb)
Moderate or Severe Active Crohn’s Disease
IVChildren ≥6 years of age: 5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 47 86 87 167
Ulcerative Colitis (Infliximab)
Moderate to Severe Active Ulcerative Colitis
IVChildren ≥6 years of age: 5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1
Adults
Crohn’s Disease (Infliximab or Infliximab-dyyb)
Moderate or Severe Active Crohn’s Disease or Fistulizing Crohn’s Disease
IV5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167
Consider dose of 10 mg/kg for patients who respond initially but subsequently lose response.1 167
Patients who do not respond by week 14 are unlikely to respond with continued administration; consider discontinuing the drug.1 167
Rheumatoid Arthritis (Infliximab or Infliximab-dyyb)
Moderate to Severe Active Rheumatoid Arthritis
IV3 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167
Increase dosage up to 10 mg/kg and/or administer as often as once every 4 weeks for patients who have an incomplete response to 3 mg/kg; consider that risk of serious infection is increased with higher dosages.1 72 167
Ankylosing Spondylitis (Infliximab or Infliximab-dyyb)
IV
5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 6 weeks (maintenance regimen).1 167
Psoriatic Arthritis (Infliximab or Infliximab-dyyb)
IV
5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167
Plaque Psoriasis (Infliximab or Infliximab-dyyb)
IV
5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167
If treatment is resumed after maintenance therapy is interrupted, reinitiate with a single dose followed by maintenance therapy.1 167 (See Acute Sensitivity Reactions and also Delayed Sensitivity Reactions, under Cautions.)
Ulcerative Colitis (Infliximab or Infliximab-dyyb)
Moderate to Severe Active Ulcerative Colitis
IV5 mg/kg at 0, 2, and 6 weeks (induction regimen), then every 8 weeks (maintenance regimen).1 167
Cautions for Infliximab, Infliximab-dyyb
Contraindications
-
Doses >5 mg/kg in patients with moderate or severe heart failure.1 167 (See Cardiovascular Effects under Cautions.)
-
Prior severe hypersensitivity reaction to infliximab products; known hypersensitivity to murine proteins or any ingredient in the formulations.1 167
Warnings/Precautions
Warnings
Based on demonstration of biosimilarity, FDA considers that no clinically meaningful differences in safety exist between infliximab and infliximab-dyyb.168 No substantial differences in frequencies of adverse effects observed between infliximab and infliximab-dyyb.168 173 174 175 176 177 181 182 No new safety concerns identified in patients following a single switch from infliximab to infliximab-dyyb, compared with those receiving continuous infliximab-dyyb therapy.168 173 192
Infectious Complications
Increased risk of serious infections involving various organ systems and sites that may require hospitalization or result in death.1 159 167 Opportunistic infections caused by bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms (e.g., aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, tuberculosis) reported, particularly in patients receiving concomitant therapy with immunosuppressive agents (e.g., methotrexate, corticosteroids).1 72 118 144 155 159 Infections frequently are disseminated.1 (See Boxed Warning.)
Increased incidence of serious infections observed with concomitant use of a TNF blocking agent and anakinra or abatacept.1 152 165 (See Interactions.)
Patients >65 years of age, with comorbid conditions, and/or receiving concomitant therapy with immunosuppressive agents (e.g., corticosteroids, methotrexate) may be at increased risk of infection.1 159 167
Do not initiate infliximab products in patients with active infections, including clinically important localized infections.1 167 Consider potential risks and benefits of the drug prior to initiating therapy in patients with a history of chronic, recurring, or opportunistic infections; patients with underlying conditions that may predispose them to infections; and patients who have been exposed to tuberculosis or who have resided or traveled in regions where tuberculosis or mycoses such as histoplasmosis, coccidioidomycosis, and blastomycosis are endemic.1 159 167
Closely monitor patients during and after infliximab product therapy for signs or symptoms of infection (e.g., fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates, serious systemic illness including shock).1 155 159 167
If new infection occurs during infliximab product therapy, perform thorough diagnostic evaluation (appropriate for immunocompromised patient), initiate appropriate anti-infective therapy, and closely monitor patient.1 155 167 Discontinue infliximab product if serious infection or sepsis develops.1 34 35 44 118 155 167
Evaluate all patients for active or latent tuberculosis and for risk factors for tuberculosis prior to and periodically during therapy with infliximab products.1 72 118 159 167 When indicated, initiate appropriate antimycobacterial regimen for treatment of latent tuberculosis infection prior to infliximab product therapy.1 14 18 42 59 72 111 118 167 Also consider antimycobacterial therapy prior to use of infliximab products in individuals with a history of latent or active tuberculosis in whom an adequate course of antimycobacterial treatment cannot be confirmed and for individuals with a negative tuberculin skin test who have risk factors for tuberculosis.1 167 Consultation with a tuberculosis specialist is recommended when deciding whether to initiate antimycobacterial therapy.1 167
Monitor all patients, including those with negative tuberculin skin tests, for active tuberculosis.1 167 Strongly consider tuberculosis in patients who develop new infections while receiving infliximab products, especially if they previously have traveled to countries where tuberculosis is highly prevalent or have been in close contact with an individual with active tuberculosis.1 167 Active tuberculosis reported in some patients receiving infliximab products while receiving therapy for latent tuberculosis.1 167
Failure to recognize invasive fungal infections has led to delays in appropriate treatment.155 Serologic tests for histoplasmosis may be negative in some patients with active infection.1 167 Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.1 155 159 167 Whenever feasible, consult specialist in fungal infections when making decisions regarding initiation and duration of antifungal therapy.1 155 167
When deciding whether to reinitiate TNF blocking agent therapy following resolution of an invasive fungal infection, reevaluate risks and benefits, particularly in patients who reside in regions where mycoses are endemic.155 Whenever feasible, consult specialist in fungal infections.155
Malignancies and Lymphoproliferative Disorders
Lymphoma and other malignancies (some fatal) reported during postmarketing surveillance in children and adolescents receiving TNF blocking agents, particularly in those receiving other immunosuppressive agents (e.g., azathioprine, methotrexate) concomitantly.1 154 167 Malignancies included lymphomas (about 50% of the cases) (e.g., Hodgkin’s disease, non-Hodgkin’s lymphoma) and various other malignancies (e.g., leukemia, melanoma, solid organ cancers), including rare malignancies usually associated with immunosuppression and malignancies not usually observed in children and adolescents (e.g., leiomyosarcoma, hepatic malignancies, renal cell carcinoma).1 154 167 Median time to occurrence was 30 months (range: 1–84 months) after the initial TNF blocking agent dose.1 167 FDA has concluded that there is an increased risk of malignancy with TNF blocking agents in children and adolescents; however, the strength of the association is not fully characterized.154
Hepatosplenic T-cell lymphoma (a rare, aggressive, usually fatal T-cell lymphoma) reported mainly in adolescent and young adult males with Crohn’s disease or ulcerative colitis receiving TNF blocking agents and/or thiopurine analogs (mercaptopurine or azathioprine).1 154 160 167 Most of the patients received a combination of immunosuppressive agents, including TNF blocking agents and thiopurine analogs.1 160 167 Unclear whether occurrence is related to TNF blocking agents or combination of TNF blocking agents and other immunosuppressive agents.1 167
In controlled studies, lymphoma was reported more frequently in patients receiving infliximab or other TNF blocking agents than in control patients.1 Patients with Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis, especially those with highly active disease and/or chronic exposure to immunosuppressive therapies, may be at increased risk of lymphoma;1 28 30 38 42 160 167 may be difficult to measure added risk of TNF blocking agents, azathioprine, and/or mercaptopurine.160
Acute and chronic leukemias (some fatal) reported during postmarketing surveillance of TNF blocking agents in adults and pediatric patients, particularly in those receiving other immunosuppressive agents concomitantly.1 154 167 Leukemia (most commonly acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) generally occurred during first 2 years of therapy.154 FDA has concluded that there is a possible association between TNF blocking agents and development of leukemia; interpretation of findings is complicated because patients with rheumatoid arthritis may be at increased risk for leukemia independent of any treatment with TNF blocking agents.1 154 167
Malignancies (mainly lung cancer or head and neck malignancies) reported in more infliximab-treated than placebo-treated patients with moderate to severe COPD†; all had been heavy smokers.1 157 Exercise caution when considering infliximab product therapy in patients with moderate to severe COPD.1 167
In infliximab-treated psoriasis patients, nonmelanoma skin cancer reported more commonly in those who had received prior phototherapy; monitor psoriasis patients receiving infliximab products, especially those who have received prolonged prior phototherapy, for nonmelanoma skin cancer.1 167
Melanoma and Merkel cell carcinoma reported in patients receiving infliximab products.1 167 Periodic skin examination recommended for all patients, particularly those with risk factors for skin cancer.1 167
Other malignancies (basal cell carcinoma, breast cancer, colorectal cancer, rectal adenocarcinoma, squamous cell carcinoma) also reported during clinical studies in patients receiving infliximab.1 14 17 141
In controlled clinical studies of infliximab, the rate of malignancies other than lymphoma and nonmelanoma skin cancer was increased in infliximab-treated patients compared with control patients, but the rate was similar to the expected rate in the general population.1
In controlled studies of other TNF blocking agents in adults at increased risk for malignancies (e.g., patients with Wegener’s granulomatosis receiving concomitant cyclophosphamide), a greater proportion of malignancies occurred in patients receiving the TNF blocking agent compared with control patients.164
Some immune-related diseases (e.g., Crohn’s disease) have been shown to increase risk of cancer independent of treatment with TNF blocking agents, while for others (e.g., juvenile idiopathic arthritis) it is unknown whether there is an increased risk of cancer.154
Consider possibility of and monitor for occurrence of malignancies during and following treatment with TNF blocking agents.154 160
Exercise caution when considering infliximab product therapy in patients with a history of malignancy or when deciding whether to continue therapy in patients who develop a malignancy.1 33 34 35 44 59 64 167 Carefully consider risks and benefits of TNF blocking agents, especially in adolescent and young adult males and in those with Crohn’s disease or ulcerative colitis.1 160 167
When deciding whether to use infliximab product alone or in combination with other immunosuppressive agents, consider both the possibility of an increased risk of hepatosplenic T-cell lymphoma with combination therapy and the observed (in infliximab studies) increase in immunogenicity and hypersensitivity reactions associated with infliximab products given as monotherapy.1 167
Other Warnings and Precautions
Based on demonstration of biosimilarity, FDA considers that no clinically meaningful differences in safety exist between infliximab and infliximab-dyyb.168 No substantial differences in frequencies of adverse effects observed between infliximab and infliximab-dyyb.168 173 174 175 176 177 181 182 No new safety concerns identified in patients following a single switch from infliximab to infliximab-dyyb, compared with those receiving continuous infliximab-dyyb therapy.168 173 192
HBV Reactivation
Infliximab products associated with reactivation of HBV infection in patients who are chronic carriers of the virus (i.e., hepatitis B surface antigen-positive [HBsAg-positive]).1 144 167 Use of multiple immunosuppressive agents may contribute to HBV reactivation.1 167
Screen all patients prior to initiation of infliximab product therapy.1 167 Consultation with expert in treatment of hepatitis B is recommended for HBsAg-positive patients.1 167 Evaluate and monitor HBV carriers before, during, and for up to several months after therapy.1 167 Safety and efficacy of antiviral therapy for prevention of HBV reactivation not established.1 167 Discontinue infliximab product and initiate appropriate treatment (e.g., antiviral therapy) if HBV reactivation occurs.1 167
Not known whether infliximab products can be readministered once control of a reactivated HBV infection is achieved; caution advised in this situation.1 167
Hepatic Effects
Severe hepatic reactions (e.g., acute liver failure, jaundice, hepatitis, cholestasis, autoimmune hepatitis) reported in patients receiving infliximab products; some cases were fatal or needed liver transplantation.1 144 167 Hepatic reactions occurred between 2 weeks and >1 year following initiation of therapy; elevations of hepatic transaminase enzymes not observed prior to discovery of liver injury in many cases.1 144
Evaluate patients with signs of liver dysfunction.1 144 167 If jaundice and/or marked hepatic aminotransferase elevations (≥5 times the ULN) develop, discontinue drug and investigate hepatic abnormality.1 167
Cardiovascular Effects
Infliximab products associated with adverse outcomes in patients with heart failure (increased mortality and hospitalization due to worsening heart failure).1 139 167
Use of infliximab in patients with heart failure (NYHA class III or IV) associated with increased mortality in patients who received infliximab 10 mg/kg and with an increase in adverse cardiovascular effects (dyspnea, hypotension, angina, dizziness) in patients who received 5 or 10 mg/kg.1 Worsening heart failure (with and without identifiable precipitating factors) and new-onset heart failure (including in patients with no known preexisting cardiovascular disease and/or who were <50 years of age) reported.1 Not evaluated in patients with mild (NYHA class I or II) heart failure.1
Use infliximab products in patients with heart failure only after consideration of other treatment options.1 167 If used in patients with moderate or severe heart failure, do not exceed doses of 5 mg/kg and monitor cardiac status closely.1 167 (See Contraindications under Cautions.)
Discontinue infliximab product therapy if new or worsening symptoms of heart failure occur.1 167
Hematologic Effects
Possible leukopenia, neutropenia, thrombocytopenia, and pancytopenia, sometimes with fatal outcome.1 167 Use infliximab products with caution in patients with a history of substantial hematologic abnormalities.1 167 Consider discontinuance of the drug in patients with confirmed hematologic abnormalities.1 167
Acute Sensitivity Reactions
Acute infusion reactions consistent with hypersensitivity reactions reported within 1–2 hours after IV infusion of infliximab products.1 10 14 18 21 36 38 41 64 72 92 128 167
Signs/symptoms include urticaria, dyspnea, hypotension, fever, chills, headache, pruritus, chest pain, and/or hypertension.1 5 10 14 15 18 21 36 38 41 64 72 92 128 136 167 Anaphylactic reactions (e.g., laryngeal/pharyngeal edema, severe bronchospasm), seizures, erythematous rash, myocardial ischemia/infarction, and transient vision loss reported.1 36 128 167
Drugs for the treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids, and/or epinephrine) should be immediately available.1 72 167
Monitor patients; consider premedication; initiate infusion slowly; adjust rate or discontinue based on patient tolerance.47 72 47 72 (See Premedication and Patient Monitoring and also see Rate Titration Schedule Table under Dosage and Administration.)
Mild acute infusion reactions often controlled by slowing or discontinuing the infusion or appropriate treatment (antihistamines).1 5 10 14 18 23 28 38 42 47 72 92 167 Discontinue infliximab product immediately for severe hypersensitivity reaction; initiate appropriate therapy.1 167
In clinical studies of infliximab, patients with antibodies to the drug were 2–3 times more likely to have an infusion reaction than patients who did not have antibodies to the drug.1
Incidence of acute infusion reactions in infliximab product-treated patients may be lower in those receiving concomitant therapy with immunosuppressive agents (e.g., azathioprine, mercaptopurine, methotrexate) than in those not receiving such therapy.1 47 167
Readministration of infliximab after a period without treatment associated with a higher incidence of infusion reactions compared with regular maintenance treatment.1 In general, carefully consider risks and benefits of infliximab product readministration after a period without treatment (especially readministration as a reinduction regimen at 0, 2, and 6 weeks); in patients with psoriasis, reinitiate infliximab product treatment with a single dose followed by maintenance therapy.1 167
Delayed Sensitivity Reactions
Delayed infusion reactions first reported in patients retreated with infliximab after a period of 2–4 years.5 10 42 Reactions appear to be delayed hypersensitivity or serum sickness-like reactions.10 42 136
Discontinue infliximab product therapy for severe hypersensitivity reaction; initiate appropriate therapy.1 167
Caution when retreatment follows an extended period of time (e.g., after ≥1 year).1 10 40 42 In general, carefully consider risks and benefits of infliximab product readministration after a period without treatment (especially readministration as a reinduction regimen at 0, 2, and 6 weeks); in patients with psoriasis, reinitiate infliximab product treatment with a single dose followed by maintenance therapy.1 167
Administration of an immunosuppressive agent (e.g., azathioprine, mercaptopurine, methotrexate) for ≥3 months prior to infliximab associated with a lower rate of development of human antichimeric antibodies (HACA) and a lower rate of infusion reactions.1 18 47 72
Nervous System Effects
CNS manifestations of systemic vasculitis, seizures, and new onset or exacerbation of central or peripheral nervous system demyelinating disorders (e.g., multiple sclerosis, optic neuritis, Guillain-Barré syndrome) reported rarely in patients receiving infliximab products or other TNF blocking agents.1
Exercise caution when considering infliximab products in patients with these neurologic disorders.1 167 Consider discontinuance of the drug if these disorders develop.1 167
Immunologic Reactions and Antibody Formation
Possible formation of autoimmune antibodies.1 14 17 18 19 20 23 28 34 35 38 41 44 64 90 136 167 Lupus-like syndrome reported.1 If manifestations suggestive of lupus-like syndrome develop, discontinue infliximab product therapy.1 167
In patients receiving infliximab products, antibodies to the drug may develop.1 22 42 28 38 64 70 84 85 167 Antibody-positive patients more likely to experience an infusion reaction.1 10 23 70 85 (See Acute Sensitivity Reactions and also Delayed Sensitivity Reactions, under Cautions.)
Immunization
Avoid live vaccines (e.g., measles virus vaccine live, mumps virus vaccine live, rotavirus vaccine live oral, rubella virus vaccine live, smallpox vaccine [no longer commercially available in US], typhoid vaccine live oral, varicella virus vaccine live, yellow fever vaccine).1 167 (See Vaccines under Interactions.)
GI Effects
Safety and efficacy data in Crohn’s disease patients with intestinal strictures is limited.4 5 38 72 88 Development or worsening of intestinal strictures and/or intestinal obstruction reported rarely in these patients.4 47 70
Use with caution in Crohn’s disease patients with intestinal strictures.47 70 72
Psoriasis
New-onset psoriasis, including pustular and palmoplantar psoriasis, and exacerbation of existing psoriasis reported with TNF blocking agents, including infliximab products.1 154 167 Most patients experienced improvement following discontinuance of the TNF blocking agent.154
Consider possibility of and monitor for manifestations (e.g., new rash) of new or worsening psoriasis, particularly pustular and palmoplantar psoriasis.154
Specific Populations
Pregnancy
No adequate and well controlled studies to date.1 167 Infliximab detected for up to 6 months in serum of infants whose mothers received infliximab products during pregnancy.1 (See Pediatric Use under Cautions.)
Some clinicians suggest that pregnancy be ruled out (negative pregnancy test) before initiating therapy and that an effective contraceptive be used.110
Lactation
Not known whether infliximab products are distributed into milk.1 167 Due to potential risk in nursing infant, discontinue nursing or the drug.1 167
Pediatric Use
Safety and efficacy of infliximab products established in children ≥6 years of age with Crohn’s disease; infliximab studied in this age group only in conjunction with conventional immunosuppressive agents.1 167 Safety and efficacy of long-term (>1 year) infliximab product therapy not established.1 167
Adverse effects reported more frequently in children than in adults with Crohn’s disease who received infliximab include anemia, leukopenia, flushing, viral infection, neutropenia, bone fracture, infection, bacterial infection, and respiratory tract allergy.1
Safety and efficacy of infliximab in children ≥6 years of age with ulcerative colitis supported by clinical studies in adults and an uncontrolled study in pediatric patients 6–17 years of age; about half of these pediatric patients received immunosuppressive agents (azathioprine, mercaptopurine, or methotrexate) concomitantly at the start of the study.1 Although safety and efficacy of infliximab-dyyb for such use also established, labeled indication for infliximab in pediatric patients with ulcerative colitis was still protected by exclusivity provisions of orphan drug designation when FDA approved infliximab-dyyb biosimilar.167 168 Safety and efficacy of long-term (>1 year) therapy with infliximab not established.1
Adverse effects in infliximab-treated pediatric patients with ulcerative colitis similar to those in infliximab-treated adults with this disease.1 Proportion of patients with infections similar to that in pediatric patients with Crohn’s disease but greater than that in adults with ulcerative colitis.1
Younger children (6–11 years of age) and adolescents (12–17 years of age) with ulcerative colitis had similar overall rates of adverse effects while receiving infliximab, including infusion reactions, but a greater proportion of the younger children had serious adverse effects or discontinued infliximab because of adverse effects.1 Proportion of patients with infections was higher in the younger age group, but similar proportions of patients in both age groups had serious infections.1
Malignancies, some fatal, reported in children and adolescents who received TNF blocking agents.1 154 160 167 (See Malignancies and Lymphoproliferative Disorders under Cautions.)
Carefully assess risks and benefits when deciding whether to use infliximab products alone or in combination with other immunosuppressive agents.1 167 Use of infliximab products in the absence of other immunosuppressive agents may increase the likelihood of infliximab-specific antibody formation and increase the risk of hypersensitivity reactions.1 167 (See Acute Sensitivity Reactions, Delayed Sensitivity Reactions, and Immunologic Reactions and Antibody Formation, under Cautions.) Unclear whether reported cases of hepatosplenic T-cell lymphoma related to TNF blocking agents or use of TNF blocking agents in conjunction with other immunosuppressive agents.1 167 (See Malignancies and Lymphoproliferative Disorders under Cautions.)
Safety and efficacy of infliximab products not established in children with plaque psoriasis.1 167
Infliximab has been evaluated in children 4–17 years of age with juvenile arthritis† who had not responded adequately to methotrexate.1 153 Further study needed to evaluate safety and efficacy.1 72 104 153
Bring all vaccinations up to date prior to initiation of infliximab product therapy in all pediatric patients.1 167
Infliximab detected for up to 6 months in the serum of infants whose mothers received infliximab products during pregnancy.1 167 Infants exposed to infliximab products in utero may be at increased risk of infection; fatal disseminated BCG infection reported in an infant who received BCG vaccine after having been exposed to infliximab in utero.1 167 Infants exposed to infliximab products in utero should not receive live vaccines (e.g., BCG vaccine, rotavirus vaccine live oral) for ≥6 months after birth.1 167
Geriatric Use
Rheumatoid arthritis, plaque psoriasis: No substantial difference in safety or efficacy relative to younger adults in clinical studies of infliximab.1
Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis: Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1
Possible increased incidence of infections in geriatric patients; use infliximab products with caution.1 167 (See Infectious Complications under Cautions.)
Hepatic Impairment
Possible reactivation of HBV in patients receiving infliximab products who are chronic carriers of this virus.1 144 167
Renal Impairment
Infliximab or infliximab-dyyb not studied in patients with renal impairment.1 167
Common Adverse Effects
Infliximab: Infections (upper respiratory infection, fistula-related abscess), acute infusion reactions, delayed infusion reactions, development of autoantibodies (ANA, Anti-dsDNA), development of antibodies to infliximab, abdominal pain, increases in serum AST or ALT concentrations.1 4 5 6 10 14 15 17 18 19 20 21 23 28 38 51 64 65 67 70 136
No substantial differences in frequencies of adverse effects observed between infliximab and infliximab-dyyb.168 173 174 175 176 177 181 182
Interactions for Infliximab, Infliximab-dyyb
No formal drug interaction studies to date.1 167
Administered concomitantly with corticosteroids, mesalamine or sulfasalazine, azathioprine or mercaptopurine, and/or anti-infective agents in patients with Crohn’s disease; serum concentrations of infliximab not affected by corticosteroids, mesalamine or sulfasalazine, or anti-infectives (ciprofloxacin, metronidazole).1 5 6 38 64 69 167 (See Immunosuppressive Agents under Interactions.)
Administered concomitantly with methotrexate, corticosteroids, NSAIAs, folic acid, and narcotics in patients with rheumatoid arthritis or psoriatic arthritis.1 14 15 17 18 41 167
Administered concomitantly with corticosteroids, azathioprine or mercaptopurine, and/or 5-aminosalicylates in patients with ulcerative colitis.1 147 167 (See Immunosuppressive Agents under Interactions.)
Drugs Metabolized by Hepatic Microsomal Enzymes
Because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes.1 167
Drugs metabolized by CYP isoenzymes that have a low therapeutic index: Monitor therapeutic effect and serum concentrations following initiation or discontinuance of infliximab products; adjust dosage as needed.1 167
Biologic Agents
Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase the risk of infection.1 167
Insufficient data regarding concomitant use of infliximab products with other biologic agents used to treat the same conditions.1 167 Concomitant use not recommended because of an increased risk of infection.1 167
Immunosuppressive Agents
Incidence of some adverse immunologic reactions (e.g., infusion reactions, formation of antibodies to infliximab) decreased in patients receiving infliximab and immunosuppressive agents concomitantly.1 18 (See Acute Sensitivity Reactions, Delayed Sensitivity Reactions, and Immunologic Reactions and Antibody Formation, under Cautions.)
When deciding whether to use infliximab products alone or in combination with other immunosuppressive agents, consider both the possibility of an increased risk of hepatosplenic T-cell lymphoma with combination therapy (see Malignancies and Lymphoproliferative Disorders under Cautions) and the observed (in infliximab studies) increase in immunogenicity and hypersensitivity reactions associated with infliximab products given as monotherapy.1 167
Vaccines and Therapeutic Infectious Agents
Consult current vaccination guidelines regarding interval between vaccination and initiation of infliximab product therapy.1 167
Live vaccines: Avoid concomitant use.1 167 Risk of infections, including disseminated infections.1 167 Limited data regarding response to live vaccines or secondary transmission of infection by live vaccines.1 167 Infants exposed to infliximab products in utero should not receive live vaccines for ≥6 months after birth.1 167 (See Pediatric Use under Cautions.)
Live therapeutic infectious agents: Avoid concomitant use.1 167 Risk of infections, including disseminated infections.1 167
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Abatacept |
Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis;1 152 158 similar toxicities expected with infliximab products and abatacept1 167 |
Concomitant use not recommended1 152 158 167 Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase risk of infection1 167 |
Anakinra |
Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with anakinra and etanercept (another TNF blocking agent) in rheumatoid arthritis;1 165 167 similar toxicities expected with infliximab products and anakinra1 167 |
Concomitant use not recommended1 165 167 Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase risk of infection1 167 |
BCG for intravesical instillation |
||
Cyclosporine |
Possible effect on cyclosporine metabolism; because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes1 167 |
Monitor therapeutic effect and serum concentrations of cyclosporine following initiation or discontinuance of infliximab products; adjust dosage as needed1 167 |
Methotrexate |
Possible decreased clearance18 39 and increased concentrations of infliximab1 Possible decrease in rate of development of antibodies to infliximab 1 |
Interaction not studied specifically;13 17 18 23 25 84 85 used concomitantly in clinical studies 13 17 18 23 25 39 84 85 |
Natalizumab |
Increased risk of progressive multifocal leukoencephalopathy (PML) or other serious infections162 |
Avoid concomitant use in the management of Crohn’s disease162 |
Rituximab |
Increased risk of serious infection reported in patients who received rituximab and subsequently received a TNF blocking agent164 |
Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase risk of infection1 167 |
Theophylline |
Possible effect on theophylline metabolism; because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes1 167 |
Monitor therapeutic effect and serum concentrations of theophylline following initiation or discontinuance of infliximab products; adjust dosage as needed1 167 |
Tocilizumab |
Concomitant use not studied; possibility of increased immunosuppression and increased risk of infection1 161 167 |
Avoid concomitant use1 161 167 Use caution when switching from one biologic DMARD to another, since overlapping biologic activity may further increase risk of infection1 167 |
Warfarin |
Possible effect on warfarin metabolism; because increased levels of cytokines (e.g., TNF-α) during chronic inflammation may suppress formation of CYP isoenzymes, antagonism of cytokine activity by infliximab products may normalize formation of CYP enzymes1 167 |
Monitor therapeutic effect of warfarin following initiation or discontinuance of infliximab products; adjust dosage as needed1 167 |
Infliximab, Infliximab-dyyb Pharmacokinetics
Pharmacokinetic similarity between infliximab and infliximab-dyyb demonstrated; FDA considers that the pharmacokinetic data provide support for a totality-of-evidence determination of biosimilarity between the 2 drugs.168 174 176 177 188 193
Absorption
Infliximab: Systemic accumulation does not appear to occur in adults receiving multiple IV infusions once every 4 or 8 weeks following an initial 3-dose induction regimen.1 38 39 41
Infliximab: Peak and trough concentrations in pediatric patients 6–17 years of age with Crohn’s disease or ulcerative colitis similar to those in adults with these diseases following administration of infliximab 5 mg/kg.1
Special Populations
Infliximab: No differences observed in pharmacokinetics based on age or weight in adults with rheumatoid arthritis or Crohn’s disease.1 14 17 18 38 39 41
Distribution
Extent
Infliximab: Distribution into body tissues and fluids, including joints, has not been fully characterized.39
Infliximab products cross the placenta.1 167
Not known whether infliximab products distribute into milk.1 167
Elimination
Metabolism
Infliximab: Metabolic fate not fully characterized; the drug may be eliminated by the reticuloendothelial system.1 47
Infliximab: Not metabolized by CYP isoenzymes.39
Half-life
Infliximab: 8–12 days in adults with Crohn’s disease, rheumatoid arthritis, or plaque psoriasis.1 14 41
Infliximab: Terminal elimination half-life in pediatric patients 6–17 years of age with Crohn’s disease or ulcerative colitis similar to that reported in adults with these diseases.1
Stability
Storage
Parenteral
Powder for Injection
Infliximab: 2–8°C.1 May store unopened vial at temperatures up to 30°C for single period of up to 6 months; following removal from refrigerated storage, do not return to refrigerated storage.1
Infliximab-dyyb: 2–8°C.167
Infliximab or infliximab-dyyb: Prepare diluted solutions of the drug immediately prior to use.1 167
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Parenteral
Solution Compatibility (Infliximab)1 HID
Compatible |
---|
Sodium chloride 0.45 or 0.9% |
Solution Compatibility (Infliximab-dyyb)167
Compatible |
---|
Sodium chloride 0.9% |
Drug Compatibility (Infliximab or Infliximab-dyyb)
The manufacturers recommend that infliximab or infliximab-dyyb not be admixed with other drugs or infused in the same IV line with other drugs.1 167
Information on the physical and/or chemical compatibility with other drugs is not available.1 167
Actions
-
Has high specificity and affinity for TNF (TNF-α); does not bind to or inactivate lymphotoxin α (TNF-β).1 7 20 24 167 Prevents the binding of TNF to cell surface TNF receptors, thereby blocking the biologic activity of TNF.1 7 20 24 167
-
A chimeric human-murine immunoglobulin G1 kappa (IgG1 kappa) monoclonal antibody.1 7 20 24 167
-
The exact mechanism of the anti-inflammatory effects in Crohn’s disease or rheumatoid arthritis remain to be more fully determined; binding and neutralization of TNF appears to be a principal mechanism.1 3 5 7 8 9 25 33 37 38 39 42 43 50 57 59
-
Produced by continuous fermentation of a mouse myeloma cell line that has been transinfected with cloned DNA coding for the chimeric antibody; purified by measures to inactivate and removes viruses.1 7 20
Advice to Patients
-
A copy of the manufacturer’s patient information (medication guide) for infliximab or infliximab-dyyb should be provided to all patients prior to each infusion session.1 154 167 Importance of advising patients about potential benefits and risks of infliximab products.1 154 159 160 167 Importance of patients reading the medication guide prior to initiation of therapy and each time they receive an infusion of the drug.1 159 160 167
-
Increased susceptibility to infection.1 167 Importance of seeking immediate medical attention if signs and symptoms suggestive of infection (e.g., fever; fatigue; cough; warm, red, or painful skin; sores on the body) develop.1 167
-
Risk of lymphoma, including hepatosplenic T-cell lymphoma, leukemia, or other malignancies with use of TNF blocking agents.1 154 160 167 Importance of informing patients and caregivers about the increased risk of cancer development in children, adolescents, and young adults, taking into account the clinical utility of TNF blocking agents, the relative risks and benefits of these and other immunosuppressive drugs, and the risks associated with untreated disease.154 160 Importance of promptly informing clinicians if signs and symptoms of malignancies (e.g., unexplained weight loss; fatigue; abdominal pain; persistent fever; night sweats; easy bruising or bleeding; swollen lymph nodes in the neck, underarm, or groin; hepatomegaly or splenomegaly) occur.154 160
-
Importance of immediately notifying clinician if manifestations of liver dysfunction (e.g., jaundice, dark brown urine, right-sided abdominal pain, fever, fatigue) occur.1 167
-
Importance of informing clinician of any new or worsening medical conditions (e.g., neurologic conditions [e.g., demyelinating disorders], heart failure, autoimmune disorders [e.g., lupus-like syndrome], psoriasis, cytopenias).1 154 167
-
Importance of taking the drug as prescribed and of not altering or discontinuing therapy without first consulting with a clinician.154 160
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 167
-
Importance of informing clinician if they have recently received or are scheduled to receive a vaccine.1 167
-
For postpartum women who received infliximab or infliximab-dyyb during pregnancy, importance of informing the infant's clinician of this use since alteration of the infant's vaccination schedule may be indicated.1 167
-
Risk of acute or delayed sensitivity reactions.1 167 Importance of advising patient to seek medical advice and treatment if they develop manifestations consistent with a delayed infusion reaction.40
-
Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses or any history of cancer, tuberculosis, HBV infection, or other chronic or recurring infections.1 155 159 167
-
Importance of informing patients of other important precautionary information.1 167 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
For injection, for IV infusion |
100 mg |
Remicade |
Janssen |
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
For injection, for IV infusion |
100 mg |
Inflectra |
Pfizer |
AHFS DI Essentials™. © Copyright 2021, Selected Revisions May 21, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Janssen Biotech, Inc. Remicade (infliximab) for IV injection prescribing information. Horsham, PA; 2015 Oct.
2. Center for Biologics Evaluation and Research of the US Food and Drug Administration. Biologics license application approval letter for infliximab. Rockville, MD; 1998 Aug 24.
3. Van Hogezand RA, Verspaget HW. The future role of anti-tumour necrosis factor-α products in the treatment of Crohn’s disease. Drugs. 1998; 56:299-305. http://www.ncbi.nlm.nih.gov/pubmed/9777308?dopt=AbstractPlus
4. D’Haens G, van Deventer S, van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European Multicenter Trial. Gastroenterology. 1999; 116:1029-34. http://www.ncbi.nlm.nih.gov/pubmed/10220494?dopt=AbstractPlus
5. Targan SR, Hanauer SB, Van Deventer SJH. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997; 337:1029-35. http://www.ncbi.nlm.nih.gov/pubmed/9321530?dopt=AbstractPlus
6. van Dullemen HM, van Deventer SJH, Hommes DW et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-35.
7. Knight DM, Trinh H, Le Junming L et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993; 30:1443-53. http://www.ncbi.nlm.nih.gov/pubmed/8232330?dopt=AbstractPlus
8. Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine.1995;7:251-9.
9. Siegel SA, Shealy DJ, Nakada MT et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15-25.
10. Mouser JF, Hyams JS. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn’s disease. Clin Ther. 1999;21:932-42.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatology Association 1987: revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315-24. http://www.ncbi.nlm.nih.gov/pubmed/3358796?dopt=AbstractPlus
12. Hochberg MC, Chang RW, Dwosh I et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992; 35:498-502. http://www.ncbi.nlm.nih.gov/pubmed/1575785?dopt=AbstractPlus
13. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38:727-35. http://www.ncbi.nlm.nih.gov/pubmed/7779114?dopt=AbstractPlus
14. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999; 354:1932-9. http://www.ncbi.nlm.nih.gov/pubmed/10622295?dopt=AbstractPlus
15. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343:1594-1602. http://www.ncbi.nlm.nih.gov/pubmed/11096166?dopt=AbstractPlus
16. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc. 2001; 76:84-6. http://www.ncbi.nlm.nih.gov/pubmed/11155419?dopt=AbstractPlus
17. Antoni C; Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 1999. 17(Suppl 18):S73-7.
18. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63. (IDIS 411263).
19. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999; 48:1-4. http://www.ncbi.nlm.nih.gov/pubmed/10408141?dopt=AbstractPlus
20. Elliot MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993; 36:1681-90. http://www.ncbi.nlm.nih.gov/pubmed/8250987?dopt=AbstractPlus
21. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-10.
22. Harriman G; Harper LK; Schaible TF Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatment. Ann Rheum Dis. 1999; 58(Suppl 1):I61-4.
23. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125-7.
24. Breedveld FC. Therapeutic monoclonal antibodies. Lancet. 2000; 355:735-40. http://www.ncbi.nlm.nih.gov/pubmed/10703815?dopt=AbstractPlus
25. Feldman M, Charles P, Taylor P et al. Biological insights from clinical trials with anti-TNF therapy. Sem Immunopathol. 1998; 20:211-28.
26. Paulus HE, Egger MJ, Ward JR et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum. 1990; 33:477-84. http://www.ncbi.nlm.nih.gov/pubmed/2109613?dopt=AbstractPlus
27. Anon. Infliximab (Remicade) for Crohn’s disease. Med Lett Drugs Ther. 1999; 41:19-20. http://www.ncbi.nlm.nih.gov/pubmed/10076592?dopt=AbstractPlus
28. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13(Suppl 4):16-22.
29. Luong BT. Chong BS, Lowder DM. Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. Ann Pharmacother. 2000;34:743-60.
30. Bickston SJ, Lichtenstein GR, Arseneau KO et al. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology. 1999;117:1433-7.
31. Greenstein AJ, Mullin GE, Strauchen JA et al. Lymphoma in inflammatory bowel disease. Cancer. 1992;69:1119-21.
32. Jones M, Symmons D, Finn J et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheum. 1996;35:738-45.
33. Kavanaugh AF. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin N Am. 1998;24:593-614.
34. Furst DE, Breedveld FC, Kalden JR et al. Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis. 1999; 58:725-6. http://www.ncbi.nlm.nih.gov/pubmed/10577955?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1752816&blobtype=pdf
35. Furst DE, Breedveld FC, Burmester GR et al. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis. 1999; 58(Suppl 1):1129-30.
36. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol. 2000; 95:2395-6. http://www.ncbi.nlm.nih.gov/pubmed/11007258?dopt=AbstractPlus
37. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs. 1998;55:613-20.
38. Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761-9.
39. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59:1341-59.
40. McCloskey RV. Dear doctor letter regarding new prescribing information for infliximab. Malvern, PA: Centocor Inc; 1998 Nov 10.
41. Kavanaugh A, St. Clair EW, McCune WJ et al. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000; 27:841-50. http://www.ncbi.nlm.nih.gov/pubmed/10782805?dopt=AbstractPlus
42. Feldman M, Elliott MJ, Woody JN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Advan Immunol. 1997; 64:283-350.
43. Miani RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med. 2000;51:207-29.
44. Furst DE, Keystone E, Maini RN et al. Recapitulation of the round-table discussion—assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 1999; 38(Suppl 2):50-3. http://www.ncbi.nlm.nih.gov/pubmed/10646494?dopt=AbstractPlus
45. Schwieterman WD. FDA perspective on anti-TNF treatment. Ann Rheum Dis. 1999; 58(Suppl I):I90-1. http://www.ncbi.nlm.nih.gov/pubmed/10577981?dopt=AbstractPlus
46. O Dell JR. Anticytokine therapy—a new era in the treatment of rheumatoid arthritis?. N Engl J Med. 1999; 340:310-2. http://www.ncbi.nlm.nih.gov/pubmed/9920958?dopt=AbstractPlus
47. Reviewers’ comments (personal observations).
48. Rankin ECC, Choy EHS, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995; 34:334-42. http://www.ncbi.nlm.nih.gov/pubmed/7788147?dopt=AbstractPlus
49. Chu CQ, Field M, Feldmann M et al Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991; 34:1125-32.
50. Van Deveneter SJH. Review article: targeting TNFα as a key cytokine in the inflammatory processes of Crohn’s disease—the mechanisms of action of infliximab. Aliment Pharmacol Ther. 1999; 13(Suppl 4):3-8.
51. Rutgeerts PJ. Review article: efficacy of infliximab in Crohn’s disease—induction and maintenance of remission. Aliment Pharmacol Ther. 1999;13(Suppl 4):9-15.
52. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39:1077-81. http://www.ncbi.nlm.nih.gov/pubmed/8670314?dopt=AbstractPlus
53. Paleolog EM, Hunt M, Elliott MJ et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum. 1996; 39:1082-91. http://www.ncbi.nlm.nih.gov/pubmed/8670315?dopt=AbstractPlus
54. Paleolog EM, Young S, Stark AC et al. Modulation of anagiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998; 41:1258-65. http://www.ncbi.nlm.nih.gov/pubmed/9663484?dopt=AbstractPlus
55. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol. 1999;163:1521-8.
56. Nakada MT, Tam SH, Woulfe DS et al. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Comm. 1998; 5:491-503.
57. Maini RN, Taylor PC, Paleolog E et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis. 1999;58(Suppl 1):56-60.
58. Gabay C, Kushner I. Acute-phase proteins and other systemic responses in inflammation. N Engl J Med. 1999; 340:448-54. http://www.ncbi.nlm.nih.gov/pubmed/9971870?dopt=AbstractPlus
59. Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis. Arch Intern Med. 2000; 160: 437-44. http://www.ncbi.nlm.nih.gov/pubmed/10695684?dopt=AbstractPlus
60. Lorenz HM; Grunke M; Hieronymus T et al. In vivo blockade of tumor necrosis factor-α in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. J Rheumatol. 2000; 27:304-10. http://www.ncbi.nlm.nih.gov/pubmed/10685789?dopt=AbstractPlus
61. Taylor PC, Peters AM, Paleolog E et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arth Rheum. 2000;43:38-47.
62. Bickston SJ, Cominelli F. Treatment of Crohn’s disease at the turn of the century. N Engl J Med. 1998; 339:401-2. http://www.ncbi.nlm.nih.gov/pubmed/9691110?dopt=AbstractPlus
63. Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn’s disease. Lancet. 1997; 349:521-4. http://www.ncbi.nlm.nih.gov/pubmed/9048788?dopt=AbstractPlus
64. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999; 340:1398-405. http://www.ncbi.nlm.nih.gov/pubmed/10228190?dopt=AbstractPlus
65. Ricart E, Snadborn WJ. Infliximab for the treatment of fistulas in patients with Crohn’s disease. Gastroenterology. 1999; 117: 1247-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4343206&blobtype=pdf
66. Present DH. Infliximab for the treatment of fistulas in patients with Crohn’s disease. Gastroenterology. 1999; 117: 1248. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4343206&blobtype=pdf
67. Lofberg R. Treatment of fistulas in Crohn’s disease with infliximab. Gut. 1999; 45:642-3. http://www.ncbi.nlm.nih.gov/pubmed/10517896?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1727720&blobtype=pdf
68. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol. 1999; 26(Suppl 57):16-21.
69. Baert FJ, D’Haens GR, Peeters M et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology. 1999; 116:22-8. http://www.ncbi.nlm.nih.gov/pubmed/9869598?dopt=AbstractPlus
70. Bell S, Kamm MA. Antibodies to tumour necrosis factor α as treatment for Crohn’s disease. Lancet. 2000; 355:858-60. http://www.ncbi.nlm.nih.gov/pubmed/10752696?dopt=AbstractPlus
71. Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
72. Centocor Inc, Malvern, PA: Personal communication.
73. American College of Rheumatology Subcommittee on Rheumatoid Arthritis. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002; 46:328-46. http://www.ncbi.nlm.nih.gov/pubmed/11840435?dopt=AbstractPlus
74. Immunex. Seattle, WA: Personal communication.
75. Reviewer comments on etanercept monograph.(personal observations).
76. Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med. 1999; 131:768-74. http://www.ncbi.nlm.nih.gov/pubmed/10577301?dopt=AbstractPlus
77. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340:253-9. http://www.ncbi.nlm.nih.gov/pubmed/9920948?dopt=AbstractPlus
78. The North American Rheumatoid Arthritis Study Group. Selection of DMARD therapy in early rheumatoid arthritis. Arthritis Rheum. 1998; 41(Suppl 9):S269. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1602062&blobtype=pdf
79. Breedveld F. New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis. Eur Cytokine Netw. 1998; 9:233-8. http://www.ncbi.nlm.nih.gov/pubmed/9831171?dopt=AbstractPlus
80. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 1995; 333:137-41. http://www.ncbi.nlm.nih.gov/pubmed/7791814?dopt=AbstractPlus
81. O’Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996; 334:1287-91. http://www.ncbi.nlm.nih.gov/pubmed/8609945?dopt=AbstractPlus
82. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999; 42:1322-8. http://www.ncbi.nlm.nih.gov/pubmed/10403258?dopt=AbstractPlus
83. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997; 350:309-18. http://www.ncbi.nlm.nih.gov/pubmed/9251634?dopt=AbstractPlus
84. Rezaian MM. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Arthritis Rheum. 1999; 42:1779. Letter.
85. Maini RN, Feldmann M, Schaible T. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Arthritis Rheum. 1999; 42:1779-81. Reply.
86. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr. 2000; 137:192-6. http://www.ncbi.nlm.nih.gov/pubmed/10931411?dopt=AbstractPlus
87. Kugathasan S, Werlin SL, Martinez A et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol. 2000; 95:3189-94. http://www.ncbi.nlm.nih.gov/pubmed/11095340?dopt=AbstractPlus
88. Hanauer SB, Meyers S. Management of Crohn’s disease in adults. Am J Gastroenterol. 1997; 92:559-65. http://www.ncbi.nlm.nih.gov/pubmed/9128300?dopt=AbstractPlus
89. Nikolaus S, Raedler A, Kuhbacher T et al. Mechanisms in failure of infliximab for Crohn’s disease. Lancet. 2000; 356:1475-9. http://www.ncbi.nlm.nih.gov/pubmed/11081530?dopt=AbstractPlus
90. Charles PJ, Smeenk RJT, De Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheumatism. 2000; 43:2383-90. http://www.ncbi.nlm.nih.gov/pubmed/11083258?dopt=AbstractPlus
91. Working Party of the British Society for Rheumatology. Guidelines for prescribing TNF-α-blockers in adults with RA. London; British Society for Rheumatology: 2000 Apr 14.
92. Puchner TC, Kugathasan S, Kelly KJ et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn’s disease patients with prior anaphylactic reaction. Inflamm Bowel Dis. 2001; 7:34-7. http://www.ncbi.nlm.nih.gov/pubmed/11233658?dopt=AbstractPlus
93. Hassard PV, Binder SW, Nelson V et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet’s disease: a case report. Gastroenterology. 2001; 120:995-9. http://www.ncbi.nlm.nih.gov/pubmed/11231954?dopt=AbstractPlus
94. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). Rockville, MD; 2001 March. From FDA web site. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm
95. Plevy SE, Landers CJ, Prehn J et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol. 1997; 159:6276-82. http://www.ncbi.nlm.nih.gov/pubmed/9550432?dopt=AbstractPlus
96. Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994; 106:1455-66. http://www.ncbi.nlm.nih.gov/pubmed/8194690?dopt=AbstractPlus
97. MacDonald TT, Hutchings P, Choy MY et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990; 81:301-5. http://www.ncbi.nlm.nih.gov/pubmed/2117510?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1535044&blobtype=pdf
98. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: first anniversary clinical experience. Am J Gastroenterol. 2000; 95:3469-77. http://www.ncbi.nlm.nih.gov/pubmed/11151879?dopt=AbstractPlus
99. Farrell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000; 95:3490-7. http://www.ncbi.nlm.nih.gov/pubmed/11151882?dopt=AbstractPlus
100. Warris A, Bjorneklett A. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001; 344:1099-100. http://www.ncbi.nlm.nih.gov/pubmed/11291675?dopt=AbstractPlus
101. Keenan GF, Schaible TF, Boscia JA. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001; 344:1099-100.
102. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet’s syndrome with infliximab. Rheumatology. 2001; 40:473-4. http://www.ncbi.nlm.nih.gov/pubmed/11312390?dopt=AbstractPlus
103. Elliott MJ, Woo P, Charles P et al. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-α (cA2). Br J Rheumatol. 1997; 36:589-93. http://www.ncbi.nlm.nih.gov/pubmed/9189062?dopt=AbstractPlus
104. Gerloni V, Pontikaki I, Desiati F et al. Infliximab in the treatment of persistently active refractory juvenile idiopathic (chronic) arthritis: a short-term pilot study. American College of Rheumatology 64th Annual Scientific Meeting, Philadelphia, PA, Oct 30 to Nov 2 2000. Abstract No. 1139.
105. Ogilvie ALJ, Antoni C, Dechant C et al. Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment of methotrexate. Br J Dermatol. 2001; 144:587-9. http://www.ncbi.nlm.nih.gov/pubmed/11260020?dopt=AbstractPlus
106. Dechant C, Antoni C, Wendler J et al. One year outcome of patients with severe psoriatic arthritis treated with infliximab. American College of Rheumatology 64th Annual Scientific Meeting, Philadelphia, PA, Oct 30 to Nov 2 2000. Abstract No. 212.
107. Kirby B, Marsland AM, Carmichael AJ et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol. 2001; 26:27-9. http://www.ncbi.nlm.nih.gov/pubmed/11260172?dopt=AbstractPlus
108. Van den Bosch F, Kruithof E, Baeten D et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000; 59:428-33. http://www.ncbi.nlm.nih.gov/pubmed/10834859?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1753171&blobtype=pdf
109. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum. 2000; 43:1346-52. http://www.ncbi.nlm.nih.gov/pubmed/10857793?dopt=AbstractPlus
110. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000; 160:610-9. http://www.ncbi.nlm.nih.gov/pubmed/10724046?dopt=AbstractPlus
111. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161: S221-7. (Also published in: MMWR. 2000; 49[No. RR-6]:1-51)
112. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001; 7:83-8. http://www.ncbi.nlm.nih.gov/pubmed/11383595?dopt=AbstractPlus
113. Lichtenstein GR. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis. 2001; 7:89-93.
114. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2001; 7(Suppl 1):S30-3. http://www.ncbi.nlm.nih.gov/pubmed/11380041?dopt=AbstractPlus
115. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet’s syndrome with infliximab. Rheumatology. 2001; 40:473-4. http://www.ncbi.nlm.nih.gov/pubmed/11312390?dopt=AbstractPlus
116. Sfikakis PP, Theodossiadis PG, Katsiari CG et al. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001; 358:295-6. http://www.ncbi.nlm.nih.gov/pubmed/11498218?dopt=AbstractPlus
117. Stone M, Salonen D, Lax M et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol. 2001; 28:1605-14. http://www.ncbi.nlm.nih.gov/pubmed/11469469?dopt=AbstractPlus
118. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab a tumor necrosis factor α neutralizing agent. N Engl J Med. 2001; 345:1098-104. http://www.ncbi.nlm.nih.gov/pubmed/11596589?dopt=AbstractPlus
119. Anon. Anakinra (Kineret) for rheumatoid arthritis. Med Lett Drugs Ther. 2002; 44:18-19. http://www.ncbi.nlm.nih.gov/pubmed/11856953?dopt=AbstractPlus
120. Hickling P, Jacoby RK, Kirwan JR and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol. 1998; 37:930-6. http://www.ncbi.nlm.nih.gov/pubmed/9783756?dopt=AbstractPlus
121. Kirwan JR for the Arthritis and Rheumatism Council low-dose glucocorticoid study group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med. 1995; 333:142-7. http://www.ncbi.nlm.nih.gov/pubmed/7791815?dopt=AbstractPlus
122. Zhang Z, Correa H, Beágueá RE. Tuberculosis and treatment with infliximab. N Engl J Med. 2002; 346:624.
123. Keane J, Gershon SK, Braun MM. Tuberculosis and treatment with infliximab. N Engl J Med. 2002; 346:625-6.
124. Wagner TE, Huseby ES, Huseby JS. Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn’s disease after treatment with a tumor necrosis factor-α inhibitor. Am J Med. 2002; 112:67-9. http://www.ncbi.nlm.nih.gov/pubmed/11812409?dopt=AbstractPlus
125. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med. 2002; 112:78. http://www.ncbi.nlm.nih.gov/pubmed/11812415?dopt=AbstractPlus
126. Marotte H, Charrin JE, Miossec P. Infliximab-inducted aseptic meningitis. Lancet. 2001; 358:1784. http://www.ncbi.nlm.nih.gov/pubmed/11734240?dopt=AbstractPlus
127. Baldassano R, Braegger CP, Escher JC et al. Infliximab (Remicade) in the treatment of pediatric Crohn’s disease. Am J Gastroenterol. 2003; 98:833-8. http://www.ncbi.nlm.nih.gov/pubmed/12738464?dopt=AbstractPlus
128. Lankarani KB. Mortality associated with infliximab. J Clin Gastroenterol. 2001; 33:255-6. http://www.ncbi.nlm.nih.gov/pubmed/11500623?dopt=AbstractPlus
129. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology. 2002; 41:116-7. http://www.ncbi.nlm.nih.gov/pubmed/11792895?dopt=AbstractPlus
130. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002; 78:47-8. http://www.ncbi.nlm.nih.gov/pubmed/11796874?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1742233&blobtype=pdf
131. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001; 357:1842-7. http://www.ncbi.nlm.nih.gov/pubmed/11410193?dopt=AbstractPlus
132. Furst DE, Breedveld FC, Burmester GR et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis. 2000; 59(suppl 1):11-12.
133. Emery P, Reginster J-Y, Appelboom T et al. WHO collaborating centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology. 2001; 40:699-702. http://www.ncbi.nlm.nih.gov/pubmed/11426031?dopt=AbstractPlus
134. Pisetsky DS, St. Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA. 2001; 286:2787-90. http://www.ncbi.nlm.nih.gov/pubmed/11735734?dopt=AbstractPlus
135. de’ Clari F, Salani, I, Safwan E, et al. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-α have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation. 2002; 105:183e. From web site. http://www.ahajournals.org
136. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541-49. http://www.ncbi.nlm.nih.gov/pubmed/12047962?dopt=AbstractPlus
137. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359:1187-93. http://www.ncbi.nlm.nih.gov/pubmed/11955536?dopt=AbstractPlus
138. Maksymowych WP, Jhangri GS, Lambert RG et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002: 29:959-65.
139. Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-(α), in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTCH) trial. Circulation. 2003; 107:3133-40. http://www.ncbi.nlm.nih.gov/pubmed/12796126?dopt=AbstractPlus
140. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004; 350:876-85. http://www.ncbi.nlm.nih.gov/pubmed/14985485?dopt=AbstractPlus
141. Fiocchi C. Closing fistulas in Crohn’sdisease — Should the accent be on maintenance or safety? N Engl J Med. 2004; 350:934-6. Editorial.
142. Panaccione R, Fedorak RN, Aumais G et al. Canadian Association of Gastroenterology clinical practice guidelines: the use of infliximab in Crohn’s disease. Can J Gastroenterol. 2004; 18:503-8. http://www.ncbi.nlm.nih.gov/pubmed/15372114?dopt=AbstractPlus
143. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology. 2003; 125:1503-1507.
144. Everitt DE. Centocor. Dear health care professional letter regarding hepatotoxicity and new risk of infections associated with Remicade (infliximab). Malvern, PA; 2004 Dec. From FDA web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm155493.htm
145. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004; 50:3432-43. http://www.ncbi.nlm.nih.gov/pubmed/15529377?dopt=AbstractPlus
146. Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004; 38:1261-5. http://www.ncbi.nlm.nih.gov/pubmed/15127338?dopt=AbstractPlus
147. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-76. http://www.ncbi.nlm.nih.gov/pubmed/16339095?dopt=AbstractPlus
148. Furst DF, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic disease, 2005. Ann Rheum Dis. 2005; 64:iv2-14. http://www.ncbi.nlm.nih.gov/pubmed/16239380?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1766920&blobtype=pdf
149. Anon. Drugs for rheumatoid arthritis. Treat Guidel Med Lett. 2005; 3:83-90.
150. Weinblatt ME. Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum. 2003; 48:35-45. http://www.ncbi.nlm.nih.gov/pubmed/12528101?dopt=AbstractPlus
152. Bristol-Myers Squibb. Orencia (abatacept) prescribing information. Princeton, NJ; 2011 Sep.
153. Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56:3096-106. http://www.ncbi.nlm.nih.gov/pubmed/17763439?dopt=AbstractPlus
154. Food and Drug Administration, Center for Drug Evaluation and Research. Information for healthcare professionals: Tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). FDA alert. Rockville MD; 2009 Aug 4. Available from FDA website (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm). Accessed 2009 Nov 3. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM070725
155. Food and Drug Administration, Center for Drug Evaluation and Research. FDA alert: Information for healthcare professionals Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). Rockville MD: Food and Drug Administration; 2008 Sep 4. Available from FDA website. Accessed 2008 Oct 20. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm
156. Remicade (infliximab) risk evaluation and mitigation strategy (REMS). From FDA website (http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM193310.pdf). Accessed 2010 Jul 27.
157. Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175:926-34. http://www.ncbi.nlm.nih.gov/pubmed/17290043?dopt=AbstractPlus
158. Biovitrum AB. Kineret (anakinra) for injection prescribing information. Stockholm, Sweden; 2010 May.
159. Food and Drug Administration. FDA drug safety communication: Drug labels for the tumor necrosis factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. Rockville, MD; 2011 Sep 7. From FDA website. Accessed 2011 Oct 2. http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm
160. Food and Drug Administration. FDA drug safety communication: Safety review update on reports of hepatosplenic T-cell lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine. Rockville, MD; 2011 Apr 14. From FDA website. Accessed 2011 Jul 26. http://www.fda.gov/Drugs/DrugSafety/ucm250913.htm
161. Genentech. Actemra (tocilizumab) injection prescribing information. South San Francisco, CA; 2011 Apr.
162. Biogen Idec Inc. Tysabri (natalizumab) injection prescribing information. Cambridge, MA; 2011 Sep.
163. Genentech. Rituxan (rituximab) injection prescribing information. South San Francisco, CA; 2011 Apr.
164. Abbott Laboratories. Humira (adalimumab) injection prescribing information. North Chicago, IL; 2011 Sep.
165. Biovitrum. Kineret (anakinra) injection prescribing information. Thousand Oaks, CA; 2009 Dec 15.
166. US Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS). Available from FDA website. Accessed 2011 Nov 3. http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm
167. Pfizer, Inc. Inflectra (infliximab-dyyb) for IV injection prescribing information. New York, NY; 2016 Aug.
168. Food and Drug Administration, Center for Drug Evaluation and Research. Application number 125544Orig1s000: Summary review. From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000SumR.pdf
169. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs), annex 2, technical report series No 977 2009. From World Health Organization website. Accessed 2017 Jan 26. http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1
170. Food and Drug Administration. Information for healthcare professionals (biosimilars). Silver Spring, MD; 2016 May 10. From FDA web site. Accessed 2016 Nov 23. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241719.htm
171. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. From FDA website. Accessed 2016 Nov 23. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
172. Griffith N, McBride A, Stevenson JG et al. Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists. Hosp Pharm. 2014; 49:813-25. http://www.ncbi.nlm.nih.gov/pubmed/25477613?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4252185&blobtype=pdf
173. Yoo DH, Prodanovic N, Jaworski J et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017; 76:355-363. http://www.ncbi.nlm.nih.gov/pubmed/27130908?dopt=AbstractPlus
174. Yoo DH, Racewicz A, Brzezicki J et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016; 18:82. http://www.ncbi.nlm.nih.gov/pubmed/27038608?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4818886&blobtype=pdf
175. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72:1605-12. http://www.ncbi.nlm.nih.gov/pubmed/23687259?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3786643&blobtype=pdf
176. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72:1613-20. http://www.ncbi.nlm.nih.gov/pubmed/23687260?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3786641&blobtype=pdf
177. Park W, Yoo DH, Jaworski J et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016; 18:25. http://www.ncbi.nlm.nih.gov/pubmed/26795209?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4721187&blobtype=pdf
179. Schellekens H, Lietzan E, Faccin F et al. Biosimilar monoclonal antibodies: the scientific basis for extrapolation. Expert Opin Biol Ther. 2015; 15:1633-46. http://www.ncbi.nlm.nih.gov/pubmed/26365396?dopt=AbstractPlus
180. McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014; 28:313-21. http://www.ncbi.nlm.nih.gov/pubmed/24723086?dopt=AbstractPlus
181. Yoo DH, Oh C, Hong S et al. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. Expert Rev Clin Immunol. 2015; 11 Suppl 1:S15-24.
182. Baji P, Péntek M, Czirják L et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ. 2014; 15 Suppl 1:S53-64.
183. Nikiphorou E, Kautiainen H, Hannonen P et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015; 15:1677-83. http://www.ncbi.nlm.nih.gov/pubmed/26549204?dopt=AbstractPlus
188. Park W, Lee SJ, Yun J et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol. 2015; 11 Suppl 1:S25-31. http://www.ncbi.nlm.nih.gov/pubmed/26395834?dopt=AbstractPlus
189. World Health Organization. Guidelines on evaluation of monoclonal antibodies as 5 similar biotherapeutic products (SBPs). 2016. From World Health Organization website. Accessed 2017 Feb 27. http://www.who.int/biologicals/BS2290_mAb-SBP_DB_Kai_LINE_NOs_20_July_2016.pdf
190. Food and Drug Administration, Center for Drug Evaluation and Research. Application number 125544Orig1s000: Chemistry review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000ChemR.pdf
191. Food and Drug Administration. Search orphan drug designations and approvals. From FDA website. Accessed 2017 Feb 27. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=175903
192. Park W, Yoo DH, Miranda P et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017; 76:346-354. http://www.ncbi.nlm.nih.gov/pubmed/27117698?dopt=AbstractPlus
193. Food and Drug Administration. Center for Drug Evaluation and Research. Application number 125544Orig1s000: Clinical pharmacology and biopharmaceutics review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000ClinPharmR.pdf
HID. ASHP’s interactive handbook on injectable drugs. McEvoy, GK, ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; Updated 2016 Jul 8. From HID website http://www.interactivehandbook.com
Frequently asked questions
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?
- What are the new drugs for the treatment of plaque psoriasis?
- How many biosimilars have been approved in the United States?
- What is the difference between Inflectra and Remicade?
- What is the difference between Renflexis and Remicade?
- What is the difference between Ixifi and Remicade?
More about infliximab
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 193 Reviews
- Drug class: antirheumatics
- FDA Alerts (4)
Consumer resources
Professional resources
Other brands: Remicade, Inflectra, Renflexis, Avsola